Pharma BD Deal Intelligence
2009 · Licensing/Option · $335M · Complete
Roche expanded its 2006 collaboration with Plexxikon into a second development and commercialization agreement for PLX4032 (vemurafenib), a BRAF inhibitor for metastatic melanoma, in a deal valued at ~$335M.
← Browse all deals · How we score deals